A Phase 1 interventional study of CP-690,550 in End-Stage Renal Disease and Hemodialysis, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-12-18.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Kidney Failure, Chronic by Pfizer — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Pfizer.
Among the 10 studies in Kidney Failure, Chronic by Pfizer, this one is the 9th largest by enrollment, is the only one that started in 2003, is one of 4 in phase 1, and was the 8th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 10 studies in Kidney Failure, Chronic by Pfizer is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 161 across the 10 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Kidney Failure, Chronic by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis. If significant non-renal clearance of the drug occurred such that dialyzability of CP-690,550 could not be assessed in Period 1, a second period (Period 2) will be conducted. In Period 2, a single dose of drug will be administered approximately 4 hours prior to hemodialysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CP-690,550
CP-690,550 10 mg oral powder for constitution
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hours (hrs) post-dose in Period 1
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1
Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1
Oral Clearance (CLpo)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing given dose of drug with AUC.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1
Dialyser Clearance (CL HD) From 0 to 1 Hour
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided (/) by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
Time frame: 0 to 1 hrs during hemodialysis started 4 hrs post-dose in Period 2
Dialyser Clearance (CL HD) From 1 to 2 Hour
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
Time frame: 1 to 2 hrs during hemodialysis started 4 hrs post-dose in Period 2
Dialyser Clearance (CL HD) From 2 to 3 Hour
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
Time frame: 2 to 3 hrs during hemodialysis started 4 hrs post-dose in Period 2
Dialyser Clearance (CL HD) From 3 to 4 Hour
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
Time frame: 3 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2
Fraction of Unbound Drug (fu)
Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.
Time frame: 2 hours post-dose in Period 1
Overall Dialyser Clearance (CL HD)
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
Time frame: 0 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2
Dialyser Clearance (CL HD) From 3 to 3.5 Hour
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
Time frame: 3 to 3.5 hrs during hemodialysis started 4 hrs post-dose in Period 2
| Milestone | CP-690,550 (10 mg OPC) |
|---|---|
| Started | 12 |
| Completed | 11 |
| Not completed | 1 |
| Withdrew: Protocol violation | 1 |
| Milestone | CP-690,550 (10 mg OPC) |
|---|---|
| Started | 11 |
| Completed | 11 |
| Not completed | 0 |
| Milestone | CP-690,550 (10 mg OPC) |
|---|---|
| Started | 11 |
| Completed | 11 |
| Not completed | 0 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| nanogram*hour/milliliter (ng*hr/mL) | CP-690,550 (Period 1) |
|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] | 396 ± 158 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
| ng*hr/mL | CP-690,550 (Period 1) |
|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) | 385 ± 151 |
| nanogram/milliliter (ng/mL) | CP-690,550 (Period 1) |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 106 ± 23.9 |
| hr | CP-690,550 (Period 1) |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 0.5 (0.5 to 0.5) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | CP-690,550 (Period 1) |
|---|---|
| Plasma Decay Half-Life (t1/2) | 3.46 ± 1.18 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing given dose of drug with AUC.
| milliliter/minute (mL/min) | CP-690,550 (Period 1) |
|---|---|
| Oral Clearance (CLpo) | 501 ± 243 |
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided (/) by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
| mL/min | CP-690,550 (Period 2) |
|---|---|
| Dialyser Clearance (CL HD) From 0 to 1 Hour | 311 ± 124 |
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
| mL/min | CP-690,550 (Period 2) |
|---|---|
| Dialyser Clearance (CL HD) From 1 to 2 Hour | 325 ± 138 |
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
| mL/min | CP-690,550 (Period 2) |
|---|---|
| Dialyser Clearance (CL HD) From 2 to 3 Hour | 332 ± 135 |
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
| mL/min | CP-690,550 (Period 2) |
|---|---|
| Dialyser Clearance (CL HD) From 3 to 4 Hour | 292 ± 111 |
Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.
| ratio | CP-690,550 (Period 1) |
|---|---|
| Fraction of Unbound Drug (fu) | 0.390 ± 0.042 |
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
| mL/min | CP-690,550 (Period 2) |
|---|---|
| Overall Dialyser Clearance (CL HD) | 318 ± 132 |
Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).
| mL/min | CP-690,550 (Period 2) |
|---|---|
| Dialyser Clearance (CL HD) From 3 to 3.5 Hour | 377 ± 200 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CP-690,550 (Period 1) | — | 0/12 (0%) | 5/12 (41.7%) |
| CP-690,550 (Period 2) | — | 0/11 (0%) | 4/11 (36.4%) |
| Event | CP-690,550 (Period 1) | CP-690,550 (Period 2) |
|---|---|---|
| HeadacheGeneral disorders | 2/12 | 0/11 |
| DyspepsiaGastrointestinal disorders | 0/12 | 1/11 |
| EcchymosisBlood and lymphatic system disorders | 0/12 | 1/11 |
| HypoglycemiaMetabolism and nutrition disorders | 1/12 | 1/11 |
| DizzinessNervous system disorders | 0/12 | 1/11 |
| ParesthesiaNervous system disorders | 0/12 | 1/11 |
| Cough increasedRespiratory, thoracic and mediastinal disorders | 1/12 | 1/11 |
| Respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 0/12 | 1/11 |
| PainGeneral disorders | 1/12 | 0/11 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/12 | 0/11 |
| Age Continuous(years) | Entire Study Population |
|---|---|
| Mean | 45.9 ± 7.9 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 2 |
| Male | 10 |
The record gives a start of Feb 2003, a primary completion of Jun 2003 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 9 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib